Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 8%
Buy 8%
Hold 58%
Sell 25%
Strong Sell 0%

Bulls say

Moderna is projected to see product sales rise significantly, from $1.73 billion in 2025 to $2.15 billion in 2026, indicating robust revenue growth potential. The company is optimizing its balance sheet through a $1.5 billion debt deal, which enhances financial flexibility amid uncertainties and allows for strategic opportunities. Improvements in manufacturing efficiency are expected to boost gross margins back to 50% in 2025, signaling a recovery from previous compressions and bolstering overall profitability as the firm's diverse mRNA pipeline advances.

Bears say

Moderna's stock outlook has turned negative primarily due to declining revenue from COVID-19 vaccine sales, which fell from $18 billion in 2022 to an anticipated $6.7 billion in 2023, with projections for further reductions in the coming years as vaccination rates decrease and the pandemic shifts toward an endemic phase. Additionally, the company's mRESVIA in respiratory syncytial virus (RSV) faces significant competition from already approved vaccines, limiting potential market share and revenue prospects. Given these factors, along with a slow pipeline progress outside of respiratory vaccines and anticipated low EU sales for 2024 and likely 2025, Moderna's long-term revenue growth potential appears substantially constrained, leading to a revised valuation of their COVID-related asset portfolio.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 8% recommend Buy, 58% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.